BASEL, Switzerland & SUWON, South Korea–(BUSINESS WIRE)–Under the agreement, Alentis and PinotBio will discover and develop next-generation antibody-drug conjugates targeting claudin-1 for oncology.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.